Pretomanid

普托马尼

Report date: 2024/12/04 11:55:14
NMEFirst In ClassQIDP

Base Information

Drug NamePretomanid
Drug Alias Name普托马尼pretomanid普瑞玛尼pretomanidumPretomanid FGK +[6] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Nitroimidazole antibiotics
Mechanisms of ActionNitric oxide donorsCell wall inhibitorsProtein synthesis inhibitors +[4] 
TargetsDNA
Therapy Area/IndicationsRenal InsufficiencyTuberculosis, PulmonaryTuberculosis, Multidrug-Resistant +[4] 
Global Approved IndicationsTuberculosis, Multidrug-ResistantTuberculosis
Approved Indications in ChinaTuberculosis
Original Approved Country/TerritoryUnited States
Original Approved Date2019/08/14
Country/TerritoryUnited StatesThailandSouth Africa +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesFgk Representative Service GmbhJohns Hopkins UniversityMylan Laboratories Ltd +[6] 
Inactive CompaniesShanghai Suntech Pharmaceutical Co LtdShanghai Fosun Pharmaceutical Industrial Development Co Ltd
Active IndicationsRenal InsufficiencyTuberculosis, PulmonaryTuberculosis, Multidrug-Resistant +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeJ04
Related LinksWikipediaDrugBankKEGG